Jeff Sessions Commitment to Religious Freedom (Vaccines?)
Leave a reply
Italy’s final vote: No mandatory vaccines
League leader Matteo Salvini called required vaccines “useless” and said they were “in many cases dangerous, if not harmful”.
Now, they won’t be required.
By a vote of 148 to 110 in the upper house of parliament, Italy has squashed mandatory vaccine laws and aims to be “more inclusive. READ MORE…
NOTE: The Democratic party passed the original mandatory vaccine law in June of 2017, but now, a year later and in the midst of a revolution in Italy, parents will no longer have to comply. The Democrats originally used a measles outbreak as the fuel for the law’s passage.
VLA Comment: Check out the summary of Italian commission report…
The $250 Biohack That’s Revolutionizing Life With Diabetes
DIYers used a security flaw to bypass the $8.3 billion insulin delivery business with a cobbled-together artificial pancreas. Read more…
Aluminum Adjuvants in Vaccines: Testing a substitute adjuvant with new HepB shot
In February 2018, the FDA and CDC approved the recommendation for a new hepatitis B vaccine, Heplisav-B targeting adults over the age of 18. The U.S. Food and Drug Administration (FDA) had twice rejected the application for licensure for Heplisav-B in the past four years because of safety signals. Heplisav-B differs from other licensed hepatitis B vaccines in that it contains a new synthetic adjuvant known as cytosine phosphoguanine 1018 (CpG 1018) composed of short synthetic DNA molecules. In 2016, the FDA rejected an application for licensure for the Heplisav-B vaccine, because the agency was concerned about an increased rate of heart attacks and deaths in people who had been given the vaccine. During the trial, approximately 14 subjects had heart attacks. In July 2017, the FDA committee convened to re-evaluate the scientific evidence and make a decision on whether Heplisav B should or should not be approved for use in the U.S. This committee had only one cardiologist on the team, Milton Packer, MD, who is a distinguished scholar in cardiovascular science at the Baylor University Medical Center in Dallas, Texas. According to Dr. Packer, it was possible that the Heplisav B vaccine’s novel adjuvant was related to the higher number of heart attacks in study participants who received the experimental vaccine. He stated: “To know if the 7 -1 heart attack imbalance represented a real risk, we’d need comparative data in 50,000 people.” However, the only way to conduct such a large trial would be to approve the vaccine and see what happens in the public. With Dr. Packer abstaining in his vote to recommend the vaccine, the FDA committee approved it anyway. Dr. Packer stated: “Why did I abstain? Based on the available data, it was impossible for anyone to know if the increase in heart attack risk was real. There is a simple rule in life: if you don’t know, you should say you don’t know.” The vaccine is now available to the public, and all those who receive it are basically guinea pigs to find out if heart attacks will result from the experimental vaccine, and if it will continue to have FDA approval.
Read more…
[Impact of different adjuvants on immunogenicity of the HBV particle vaccine containing the S + preS1 fusion antigen in Balb/C mice].
Study on combining Aluminum with 1018 (CPG1018 as above)
Study: Cytochrome P450 1A1 and 1B1 promoter CpG island methylation regulates rat liver injury induced by isoniazid
Brazil Judge suspends use of Glyphosate
A Brazilian judge has suspended the use of products containing the agrochemical glyphosate, a widely employed herbicide for soy and other crops in the country, according to legal filings.
A federal judge in Brasilia ruled that new products containing the chemical could not be registered in the country and existing registrations would be suspended within the next 30 days, until the government reevaluates their toxicology.
The decision, which could be subject to multiple appeals, also applies to the insecticide abamectin and the fungicide thiram.
The ruling affects companies such as Monsanto Co, which markets a glyphosate-resistant, genetically-modified type of soybean that is planted on a large scale in Brazil. Monsanto is now a unit of Bayer AG, following a $62.5 billion takeover of the U.S. seed major which closed in June.
VACCINE SAFETY GRANTS: NIH Sept 2018
HPV (Gardasil) Cochrane BOGUS STUDY details
What happened to Cochrane?
Cochrane, a non-profit organization whose research helps individuals make informed health decisions, published a review in May 2018 claiming that the HPV vaccine helps prevent cancer and precancerous changes in the cervix with no serious side effects. The review aimed to increase public confidence in the HPV vaccine – both its efficacy in cancer prevention and its long-term safety. This publication has the potential to affect the opinions of many people regarding the HPV vaccine, possibly reassuring some parents and convincing them to choose it
for their children. READ ARTICLE
VLA Comment: The article is interesting to read however, the link to the BMJ review of the HPV Cochrane study shows the poor and fallacious design of the study whose conclusion is that the HPV vaccine is safe. The Cochrane HPV vaccine review was incomplete and ignored important evidence of bias
THE RUSSIAN HOAX
The Russia Hoax: The Illicit Scheme to Clear Hillary Clinton and Frame Donald Trump by Gregg Jarret
Pfizer Vice President blows the whistle on ‘deadly’ vaccines.
Pfizer Vice President Dr. Peter Rost blows the whistle on ‘deadly’ vaccines.
The former vice president of the world’s largest pharmaceutical company has blown the whistle to expose the true dangers of mandatory vaccinations. Dr. Peter Rost lifted the lid on vaccines and revealed that the Gardasil inoculation, in particular, is in fact, “deadly”. In a shocking exposé from one of the highest-ranking whistleblowers to date, Rost has also claimed that Big Pharma is purposely keeping the public unhealthy so they can make a fortune from continual treatments of illnesses rather than curing them. Dr. Rost made the revelations during an interview for the “One More Girl” documentary in which he candidly discussed how the main objective for vaccines and pharmaceutical drugs is to keep the public in a constant state of disease.
READ MORE…
READ MORE…
Pilot Study: Non-invasive therapy eliminates Aluminum from Alzheimer patients
Non-invasive therapy to reduce the body
burden of aluminium in Alzheimer’s disease
Abstract. There are unexplained links between human exposure to aluminium and the incidence, progression and aetiology of Alzheimer’s disease. The null hypothesis which underlies any link is that there would be no Alzheimer’s disease in the effective absence of a body burden of aluminium. To test this the latter would have to be reduced to and retained at a level that was commensurate with an Alzheimer’s disease-free population. In the absence of recent human interference in the biogeochemical cycle of aluminium the reaction of silicic acid with aluminium has acted as a geochemical control of the biological availability of aluminium. This same mechanism might now be applied to both the removal of aluminium from the body and the reduced entry of aluminium into the body while ensuring that essential metals, such as iron, are unaffected. Based upon the premisethat urinary aluminium is the best non-invasive estimate of body burden of aluminium patients with Alzheimer’s disease were asked to drink 1.5 L of a silicic acid-rich mineral water each day for five days and, by comparison of their urinary excretion of aluminium pre-and post this simple procedure, the influence upon their body burden of aluminium was determined. Drinking the mineral water increased significantly (P <0.001) their urinary excretion of silicic acid (34.3 ± 15.2 to 55.7 ± 14.2 μmol/mmol
creatinine) and concomitantly reduced significantly (P = 0.037) their urinary excretion of aluminium (86.0 ± 24.3 to 62.2 ± 23.2 nmol/mmol creatinine). The latter was achieved without any significant (P >0.05) influence upon the urinary excretion of iron (20.7 ± 9.5 to 21.7 ± 13.8 nmol/mmol creatinine). The reduction in urinary aluminium supported the future longer-term
use of silicic acid as non-invasive therapy for reducing the body burden of aluminium in Alzheimer’s disease.